Background. Treatment of established postherpetic neuralgia (PHN) is difficult and often disappointing. In this study, we assessed the efficacy of repetitive intracutaneous injections with local anesthetics and steroids in acute thoracic herpes zoster (HZ) pain, herpetic eruption, and incidence of PHN.
Introduction
Herpes zoster (HZ) has an estimated incidence of 25% in the general population and occurs in approximately V C 2016 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 50% of those over 85 years old [1, 2] . The most frequent complication of HZ is postherpetic neuralgia (PHN), which can dramatically affect patients' quality of life. Treatment of established PHN is often disappointing, and current existing interventions are not completely effective in all cases of PHN [3] . Therefore, an important focus of current research is the development of more effective treatments for preventing PHN. The current consensus is that the early treatment of HZ results in less acute pain, accelerates the rash healing process, and reduces the incidence of developing PHN.
The concomitant inflammation of the ganglion, peripheral nerve, and nerve endings (skin damage) is supposedly responsible for HZ-associated pain [4] . This tissue damage and inflammation excites nociceptors, causing both excitation and repetitive painful stimuli leading to central sensitization of the nociceptive system, which is believed to be the most important mechanism underlying longlasting pain associated with PHN [5, 6] . Interventions that reduce the inflammation and repetitive painful stimuli during the acute phase of HZ might alleviate central sensitization (dorsal horn) and substantially decrease the development of PHN [7, 8] . Epidemiological studies have demonstrated that the incidence of PHN is proportional to the degree of pain and inflammation in acute HZ [9] . Therefore, interventions aimed at reducing the inflammation and blocking the painful stimuli from reaching the central nervous system may be effective in decreasing the occurrence of PHN. Currently, regional anesthetic techniques like epidural, paravertebral block, intrathecal, and sympathetic nerve blocks have been used in treating pain caused by HZ and PHN [10] [11] [12] [13] . While the effectiveness of the aforementioned intervention strategies on preventing of PHN is promising, they do not completely prevent the development of PHN without any risk [13] [14] [15] [16] .
An interventional strategy with significantly fewer adverse effects may be intracutaneous injections of local anesthetics and corticosteroids. Few empirical studies have described the use of intracutaneous injections in acute HZ pain [17] [18] [19] [20] . None of the available studies, however, was a well-designed randomized controlled trial for acute pain in HZ. Therefore, the purpose of this study is to evaluate the effectiveness of repetitive intracutaneous injections on acute HZ pain, duration of herpetic eruption, and incidence of PHN.
Methods

Study Design
In accordance with the Declaration of Helsinki and subsequent amendments and in compliance with the approval of the Human Ethics Committee of the First Hospital of Lianyungang City as well as good clinical practice, this study was designed as a prospective randomized placebo-controlled clinical trial from July 2010 to June 2013. Before participating, all patients signed informed consent forms.
Patients
Participants in the study were limited to those who met the following criteria: ages 50-80 years old, experiencing HZ within 7 days after onset of the rash, chest wall herpetic eruption, and HZ pain intensity 4 on the visual analog scale (VAS).
Patients were excluded if they had known allergies to the medications used, any clinically significant or unstable condition, coagulation abnormalities, infection at the site of injection, or any intolerance to the study.
Procedures
Baseline measurements of the clinical characteristics included pain intensity, the time of first injection, the number of affected dermatomes, and quality of life. The injection solution was prepared by a nurse who did not participate in the study. The injection was performed by the doctor (Cui Jizheng), and all follow-up was conducted by a second blinded doctor (Zhang Xiaobao). Using a computer-generated sequence, the study patients were assigned into one of the following groups.
Control group: The patients received the current standard treatment (antiviral medication and analgesics) for HZ. In this study, acyclovir (800 mg five times daily for 7 days) was administered to all of the patients. The patients were given tramadol (50-100 mg in accordance to both body weight and patients' tolerability) for pain control when VAS 4. The permitted maximum daily dose was 400 mg.
Intracutaneous injection group: Patients allocated to the intracutaneous injection group also received the standard treatment and intracutaneous injections of 15 ml 0.25% ropivacaine and 40 mg methylprednisolone every 48 h for a week (total 4 injections) .
The areas injected were determined according to the distribution of the skin lesions and nerve segmental distribution of the pain. The intracutaneous injections were placed along the midclavicular line, axillary line, and subscapularis line as determined by the dermtomal distribution of pain and the rash. For example, in one patient, the dermtomal distribution of pain and the lesion was T4-T6 on the right side of the body, so the solutions were injected into the right side of the midclavicular line, axillary line, and subscapularis line between T4 and T6 ( Figure 1 ). Maximum therapeutic effect cannot be anticipated unless all of the affected areas are injected. Therefore, the areas of eruption or sites of pain, burning, or itching were also selectively injected, and special consideration was given to the most painful areas. A 2-ml plastic syringe (B. Braun Omnifix V R , Germany) with a thin needle (B. Braun Omnifix; diameter: 0.40 mm, length: 20 mm) was utilized for intracutaneous injections. Each patient received intracutaneous injections of 0.5-1 ml solutions of 0.25% ropivacaine plus 40 mg methylprednisolone/per 15 ml solution at every injection point. The distance between each injection was 2 cm. A total of 15 ml solutions were injected.
Outcome Measures
Pain severity was evaluated using VAS (0 ¼ no pain, 10 ¼ worst pain imaginable) score. VAS scores were assessed at the initial visit (basal) and 1, 2, 4, 12, and 24 weeks after the end of the injections. The time of complete resolution of pain and herpes eruption was recorded for each patient. The incidence of PHN (defined as the presence of pain of any grade related to the prior outbreak) was evaluated at 1, 3, and 6 months after acute HZ.
The patients' quality of life was assessed using the Euro quality of life visual analog scale (EuroQoL VAS; 0 ¼ does not interfere, 10 ¼ complete interference) [21] at the initial visit and 1, 3, and 6 months after the treatment. The amount of tramadol (mg/d) each patient consumed was collected weekly for 4 weeks, and any side effects (bleeding at the injection site, injection pain, infection, and drug-related side effects) during the study were also recorded.
Statistical Analysis
According to the study done by Wood et al. [22] , the expected incidence of PHN in patients above 50 years old in the control group was 25%. We aimed for 5% incidence in the intracutaneous group, so the difference between the incidence of PHN in the two groups was 20%. A calculated sample size of 44 patients in each group was needed, which provided a level of statistical significance of 0.05 (a ¼ 0.05) and 80% power. Allowing for 10% loss of follow-up, 98 patients were included.
A statistical analysis was performed using SPSS version 16.0 (SPSS Inc., Chicago, IL). Continuous quantitative data were expressed as mean and standard deviation. Frequency and proportion were used for qualitative data. For quantitative data, Student's t-test with Bonferroni correction was used to compare the two groups. For qualitative data, Fisher's exact test and the v 2 test were used. P < 0.05 was considered statistically significant.
Results
A total of 96 patients were randomly allocated to the control group (n ¼ 48) and the intracutaneous group (n ¼ 48). Two patients in the control group and one patient in the intracutaneous group did not complete the study due to a loss of follow-up. There were no statistically significant differences between the two groups with respect to demographic and clinical characteristics ( Table 1 ).
The intracutaneous group reported a significantly shorter duration of pain (25.7 6 37.2 vs 58.2 6 66.5 days, P ¼ 0.005; Table 1 ). The intracutaneous group also had a significantly shorter duration of herpetic eruption and skin healing (17.9 6 7.0 vs 30.8 6 6.9 days, P < 0.001; Table 1 ). The same group also reported a significantly lower incidence of PHN after 1 month (12.8% vs 47.8%, P < 0.001), 3 months (6.4% vs 28.3%, P ¼ 0.005), and 6 months (4.3% vs 17.4%, P ¼ 0.022).
As shown in Table 2 , the VAS at baseline was similar between the two groups. Significantly lower VAS was noticed in the intracutaneous group throughout the study period.
Concerning the rescue drug's (tramadol) consumption per day, there was a significantly lower dosage in the intracutaneous group than in the control group. There was no significant difference in the incidence of drowsiness (6.1% vs 6.5%, P ¼ 1.000) and nausea or vomiting (8.5% vs 8.7%, P ¼ 1.000) between the two groups ( Table 3 ).
The quality of life (EuroQoL VAS) improved in both groups after 1, 3, and 6 months compared with the baseline. The improvement was also significant at all the follow-up time points in the intracutaneous group when compared with the control group (Table 4) .
It was noticed that injection pain was the most common side effect of the intracutaneous injection. The injection itself tends to be painful despite the use of ropivacaine, although few individuals complain of it unduly. In some individuals, especially in those of advanced age, bruising occurs at the injected sites. Other side effects, including abscesses, cutaneous atrophy, scarring, tenderness, vertigo, dizziness or giddiness, sweating, and moon face were not encountered throughout the study. 
Discussion
The findings of this randomized, placebo-controlled study show that repetitive intracutaneous injections of a 15-ml solution of ropivacaine 0.25% and methylprednisolone 40 mg/15 ml in acute thoracic HZ within 1 week of rash onset not only effectively alleviated zosterassociated pain and reduced the course of skin eruption, but also significantly reduced the incidence of PHN. Our results also demonstrated that repetitive intracutaneous injections treatment significantly reduced the average dosage of the rescue drug (tramadol) and improved the overall quality of life (EQ-VAS).
The results in the standard treatment group indicated that antiviral medications can effectively reduce acute HZ pain, hasten rash healing, and reduce the incidence of PHN [23] [24] [25] . The incidence of PHN in the standard treatment group was 47.8% at 1 month, 28.3% at 3 months, and 17.4% at 6 months after the treatment. Wood and his coworkers [22] reported the incidence of PHN was 25% at 3 months, and Schmader [26] reported the presence of PHN in 15% of patients being treated with antiviral drugs at 6 months. The slight variability among the studies may be due to different patient inclusion and exclusion criteria, different antiviral medications, and different PHN definitions.
Although intracutaneous injections with local anesthetics and corticosteroids have been used for decades both to treat zoster-associated pain and to prevent or treat PHN [17] [18] [19] 27] , the effectiveness of this treatment has not previously been evaluated in a randomized clinical trial. In 1976, Epstein [19] reported that an average of 4.4% of 111 patients with zoster developed postherpetic neuralgia. In 1981, Epstein [18] published remarkable results for a case series in which 272 patients (68% > 50 years old) suffering from acute HZ received subcutaneous daily injections with a triamcinolone mixture under the areas of eruption until acceptable pain relief was obtained; only 2.9% of those patients developed PHN. Chiarello [20] studied the effectiveness of infiltrating the dermatomes of Values are in mean 6 SD and in number (%). *Significant when compared with the other group. acute herpetic pain (defined as pain 3 months after rash onset) using a mixture of lidocaine, epinephrine, and triamcinolone solution in a series of 13 HZ patients, and reported that 8 were completely free of pain; 2 experienced almost no pain except for an occasional annoying, crawling feeling; 1 experienced a substantial reduction in pain; and 1 experienced no relief. In the current study, we compared the effects of intracutaneous injections with ropivacaine and methylprednisolone in addition to standard treatment of antiviral and oral analgesics with standard treatment in 93 HZ patients for the prevention of PHN. The intracutaneous injection group had a significantly lower incidence of PHN (12.8%, 6.4%, and 4.3% after 1, 3, and 6 months, respectively) compared with the standard treatment group (47.8%, 28.3%, and 17.4% after 1, 3, and 6 months, respectively).
In the current study, intracutaneous injection using local anesthetics plus corticosteroids resulted in lower pain intensity (VAS) and fewer doses of rescue drug (tramadol) at each follow-up time point, indicating a better quality of analgesia in the intracutaneous injection group.
The significantly shorter duration of skin eruption in the intracutaneous injection group may be attributed to the dense intracutaneous injections. These injections may have caused increased intraneural blood flow, reduced inflammation, and vasodilatation of the affected dermatomes, resulting in an accelerated resolution of skin rash and promotion of skin healing.
It is accepted that acute HZ pain intensity and PHN are well-established factors for a low quality of life [26] . In the current study, intracutaneous injections reduced both the pain intensity (VAS) and the incidence of PHN more than the standard treatment.
The shorter duration of pain and skin eruption, lower average dosage of rescue drug, lower incidence of PHN, and higher quality of life noticed in the intracutaneous injection group may be attributed to the utilization of intracutaneous injections of local anesthetics and corticosteroids. Although the actual mechanism is not established, it is known that intracutaneous injections using local anesthetics and corticosteroids have been shown to prevent the development of PHN [17] [18] [19] [20] . Reducing acute HZ pain can be achieved by blocking C-nociceptors and afferent transmission of the pain stimulus using local anesthetics. In addition, this reduction of pain may be attributed to the capacity of local anesthetics to inhibit the axonal diffusion of the varicella-zoster virus. It is recognized that corticosteroids are effective for both the zoster-associated pain and for the prevention of PHN. Applying corticosteroids at the affected dermatomes may decrease neuronal damage by hindering swelling-induced neuronal ischemia. Furthermore, the effectiveness of corticosteroids for the prevention of PHN may be a result of lysosomal protection and inhibition of the inflammatory process.
It is recognized that the treatment of HZ should be initiated as early as possible, and it is generally believed that 9-12 days are necessary for central damage to occur [23] [24] [25] 27, 28] . Our study used early (within 1 week) intracutaneous injections for treatment of HZ and thus demonstrated the clinical effect of early intracutaneous injection treatment for acute HZ. Several limitations of our study will need to be addressed in future studies. The current study was designed to be a single-center study, and the number of participants was relatively small. The follow-up time was limited to 6 months, and the systemic absorption of corticosteroid was unknown. Finally, the optimum dosage of anesthetics and corticosteroids and the frequency of rejection remain to be determined.
Conclusions
Our study demonstrated that repetitive intracutaneous injections with ropivacaine and methylprednisolone plus standard treatment with acyclovir and tramadol are more effective than the standard treatment alone in reducing the duration of pain and skin eruption, preventing PHN, decreasing the dosage of rescue drugs, and improving the quality of life.
